The use of hormonal therapy with radiotherapy for prostate cancer: analysis of prospective randomised trials

被引:19
作者
Gottschalk, AR
Roach, M
机构
[1] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94115 USA
[2] Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94115 USA
关键词
prostate cancer; hormonal therapy; radiation; whole-pelvic radiation; randomised trials;
D O I
10.1038/sj.bjc.6601625
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In 1901, Wilhelm Conrad Rontgen won the Nobel prize in Physics for his discovery of the Rontgen rays or, as he himself called them, X-rays. In 1966, Dr Charles Brenton Higgins won the Nobel Prize in Medicine for his breakthroughs concerning hormonal treatment of prostatic cancer. After 31 years, in 1997, the first prospective randomised trials of the combination of hormonal therapy and radiation therapy were published, showing increased survival when compared to radiation therapy alone for patients with prostate cancer. Since 1997, many investigators have published trials combining hormonal and radiation therapy for prostate cancer. This minireview will address the largest and most influential of these trials, and attempt to guide physicians in selecting the appropriate patients for this combined approach.
引用
收藏
页码:950 / 954
页数:5
相关论文
共 14 条
[1]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[2]   Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].
Bolla, M ;
Collette, L ;
Blank, L ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Mattelaer, J ;
Torecilla, JL ;
Pfeffer, JR ;
Cutajar, CL ;
Zurlo, A ;
Pierart, M .
LANCET, 2002, 360 (9327) :103-108
[3]   Clinical utility of the percentage of positive prostate biopsies in predicting prostate cancer-specific and overall survival after radiotherapy for patients with localized prostate cancer [J].
D'Amico, AV ;
Keshaviah, A ;
Manola, J ;
Cote, K ;
Loffredo, M ;
Iskrzytzky, O ;
Renshaw, AA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 53 (03) :581-587
[4]   The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer [J].
D'Amico, AV ;
Schultz, D ;
Silver, B ;
Henry, L ;
Hurwitz, M ;
Kaplan, I ;
Beard, CJ ;
Renshaw, AA .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 49 (03) :679-684
[5]  
Hanks G. E., 2000, International Journal of Radiation Oncology Biology Physics, V48, P112, DOI 10.1016/S0360-3016(00)80021-8
[6]   THE USE OF PROSTATE-SPECIFIC ANTIGEN, CLINICAL STAGE AND GLEASON SCORE TO PREDICT PATHOLOGICAL STAGE IN MEN WITH LOCALIZED PROSTATE-CANCER [J].
PARTIN, AW ;
YOO, J ;
CARTER, HB ;
PEARSON, JD ;
CHAN, DW ;
EPSTEIN, JI ;
WALSH, PC .
JOURNAL OF UROLOGY, 1993, 150 (01) :110-114
[7]   Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31 [J].
Pilepich, MV ;
Caplan, R ;
Byhardt, RW ;
Lawton, CA ;
Gallagher, MJ ;
Mesic, JB ;
Hanks, GE ;
Coughlin, CT ;
Porter, A ;
Shipley, WU ;
Grignon, D .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1013-1021
[8]   ANDROGEN DEPRIVATION WITH RADIATION-THERAPY COMPARED WITH RADIATION-THERAPY ALONE FOR LOCALLY ADVANCED PROSTATIC-CARCINOMA - A RANDOMIZED COMPARATIVE TRIAL OF THE RADIATION-THERAPY ONCOLOGY GROUP [J].
PILEPICH, MV ;
KRALL, JM ;
ALSARRAF, M ;
JOHN, MJ ;
DOGGETT, RLS ;
SAUSE, WT ;
LAWTON, CA ;
ABRAMS, RA ;
ROTMAN, M ;
RUBIN, P ;
SHIPLEY, WU ;
GRIGNON, D ;
CAPLAN, R ;
COX, JD .
UROLOGY, 1995, 45 (04) :616-623
[9]   Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate [J].
Pilepich, MV ;
Winter, K ;
John, MJ ;
Mesic, JB ;
Sause, W ;
Rubin, P ;
Lawton, C ;
Machtay, M ;
Grignon, D .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 50 (05) :1243-1252
[10]  
PILEPICH MV, 2003, P AN M AM SOC CLIN, V22, P381